Shared on07 May 25Fair value Increased 11%
AnalystLowTarget made no meaningful changes to valuation assumptions.
Cost Pressures And Supply Risks Will Weaken Transplant Market Viability
AnalystLowTarget's Fair Value
US$114.00
15.0% overvalued intrinsic discount09 Aug
US$131.13
1Y
-19.1%7D
4.3%